Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer
In summary, we identify synergistic molecular cross-talk between the GLP-1R and steroid hormone receptor pathways, with the potential to enhance the anticancer activity of levonorgestrel when combined with semaglutide.
Authors
- Abigail M. Morrison (ORCID: https://orcid.org/0000-0001-6935-5246)
- Ian S. Hagemann (ORCID: https://orcid.org/0000-0002-3855-9745)
- Kimberly Kay Leslie (ORCID: https://orcid.org/0000-0002-2704-8990)
- Andrea R. Hagemann (ORCID: https://orcid.org/0000-0002-3484-0046)
- Kristina W. Thiel (ORCID: https://orcid.org/0000-0001-8295-864X)
- Eric J. Devor (ORCID: https://orcid.org/0000-0001-7131-8604)
- Paige K. Malmrose
- David G. Mutch (ORCID: https://orcid.org/0000-0002-6921-1581)
- Yuping Zhang
Institutions
- University of Iowa (US)
- University of New Mexico (US)
- Washington University in St. Louis (US)
- University of Illinois Chicago (US)
- New Mexico Cancer Center (US)
- UNM Comprehensive Cancer Center
Publication Details
- Journal
- Cancers
- Published
- 2025-02-10
- DOI
- https://doi.org/10.3390/cancers17040598
- Citations
- 8
- Primary Topic
- Cancer Risks and Factors
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- U.S. Department of Defense
- National Institutes of Health